EyePoint Pharmaceuticals Q2 revenue drops on lower license income

EyePoint

05/08/2026 12:24

Overview
US retinal disease drug developer's Q2 revenue fell sharply yr/yr on lower license revenue
Q2 operating expenses rose, reflecting Phase 3 trial costs and manufacturing scale-up
Company ended Q2 with $180 mln in cash and investments, expects runway into Q4 2027

Outlook
Topline data from LUGANO Phase 3 wet AMD trial expected in August 2026
Topline data from LUCIA Phase 3 wet AMD trial anticipated in Q4 2026
Company expects cash and investments to fund operations into Q4 2027

Result Drivers
LICENSE REVENUE DECLINE - Co said revenue decrease was mainly due to recognition of remaining deferred revenue from 2023 YUTIQ license agreement
PHASE 3 TRIAL COSTS - Higher operating expenses attributed to ongoing DURAVYU Phase 3 clinical trials for wet AMD and DME
MANUFACTURING SCALE-UP - Co said increased expenses also reflected scale-up of commercial manufacturing facility

Company press release: ID:nGNX4wtR4d

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
 
$507,000
 
Q2 Net Loss
 
$94.47 mln
 
Q2 Loss Per Basic Share
 
$1.09
 
Q2 Operating Expenses
 
$97.89 mln
 
Q2 Operating Income
 
-$97.38 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for EyePoint Inc is $39.00, about 234.2% above its August 4 closing price of $11.67

Reuters Recommended Reads
Aug 3 - Ocular Therapeutix Q2 product revenue flat, net loss widens on higher spending
Aug 3 - Stoke Therapeutics Q2 revenue falls 33% on lower collaboration, licensing income
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)